title: Recombinant factor VIIa.
abstract: Human coagulation factor (F) VII is a single chain protease that circulates in the blood as a weakly active zymogen at concentrations of approximately 10 nmol/L. When converted to the active 2 chain form (FVIIa), it is a powerful initiator of haemostasis. Recombinant factor VIIa (rFVIIa, eptacog alfa, NovoSeven) is a genetically engineered product that was first introduced in 1988 for the treatment of patients with haemophilia A and B with high inhibitory antibody titres to factors VIII and IX. Recent reports in the form of case studies and series, and early trial data, have suggested a role for rFVIIa across a diverse range of indications including bleeding associated with trauma, surgery, thrombocytopaenia, liver disease and oral anticoagulant toxicity. This review describes the physiology of the coagulation pathway and in particular the role of recombinant factor VIIa. It will also focus on the emerging role of rFVIIa in both trauma and non-trauma bleeding and its potential use in the ED.
authors.affiliation: Allamanda Emergency Care Centre, Allamanda Private Hospital, Southport, Queensland, Australia. mgaitken@austarnet.com.au
authors.forename: Michael G
authors.initials: MG
authors.lastname: Aitken
mesh_terms: D001315:Australia; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004341:Drug Evaluation; D004635:Emergency Medicine / Q000379:methods*; D015942:Factor VIIa / Q000191:economics / Q000502:physiology / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology; D006487:Hemostasis / Q000502:physiology; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy; D009520:New Zealand; D011994:Recombinant Proteins; D014947:Wounds and Injuries / Q000150:complications
chemical_list: D011994:Recombinant Proteins; D015942:Factor VIIa